Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.

Leukemia - 1 Jul 2014

Tefferi A, Thiele J, Vannucchi A M, Barbui T

Abstract excerpt

Disease-specific mutations facilitate diagnostic precision and drug target discovery. In myeloproliferative neoplasms (MPN), this is best exemplified by the chronic myeloid leukemia-associated BCR-ABL1. No other mutation in MPN has thus far shown a similar degree of diagnostic accuracy or therapeutic relevance. However, JAK2 and KIT mutations are detected in more than 90% of patients with polycythemia vera and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Neoplasms
Share to Calreticulin
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Practice Guidelines as Topic

Share to Primary Myelofibrosis

Share to Receptors, Colony-Stimulating Factor

Share to Thrombocythemia, Essential

Share to World Health Organization

Source

Identifiers

PMID: 24441292
DOI: 10.1038/leu.2014.35

Genes

CALR
JAK2
MPL
ABL1
BCR
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.PMID 24441292Read ↗

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review.Semantic proximity Read ↗

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.Semantic proximity Read ↗

Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.Semantic proximity Read ↗

[Myeloproliferative neoplasms: revisions in the 2016 WHO criteria].Semantic proximity Read ↗

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisionsSemantic proximity Read ↗

Calreticulin Immunohistochemistry in Myeloproliferative Neoplasms - Evolution of a New Cost-Effective Diagnostic Tool: A Retrospective Study with Histological and Molecular Correlation.Semantic proximity Read ↗

Calreticulin Mutations in Myeloproliferative NeoplasmsSemantic proximity Read ↗

The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Frequency and Molecular Characteristics of Calreticulin Gene (CALR) Mutations in Patients with JAK2-Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Calreticulin mutations in essential thrombocythemia and primary myelofibrosis.Semantic proximity Read ↗

Calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.